

NRC FORM 591M
PART 1
(10-2003) 10 CFR
2.201

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Ballas Cancer Center 450 N. New Ballas Rd. Suite 270 St. Louis, MO 63131		2. NRC/REGIONAL OFFICE Nuclear Regulatory Commission Region III 2443 Warrenville Road, Suite 210 Lisle, Illinois 60532	
REPORT	2006/001		
3. DOCKET NUMBER(S) 030-35039	4. LICENSEE NUMBER(S) 24-32151-01	5. DATE(S) OF INSPECTION 04/24/2006	

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

1. Based on the inspection findings, no violations were identified.
2. Previous violation(s) closed.
3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy to exercise discretion, were satisfied.


_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Tony Go		04/24/2006

DOCKET FILE INFORMATION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE Ballas Cancer Center REPORT 2006/001		2. NRC/REGIONAL OFFICE Region III	
--	--	--------------------------------------	--

3. DOCKET NUMBER(S) 030-35039	4. LICENSE NUMBER(S) 24-32151-01	5. DATE(S) OF INSPECTION 04/ 24 /06
----------------------------------	-------------------------------------	--

6. INSPECTION PROCEDURES 87131, 87132	7. INSPECTION FOCUS AREAS 03.01 - 03.07
--	--

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM 2230	2. PRIORITY 2	3. LICENSEE CONTACT Todd Grigereit, Ph.D.	4. TELEPHONE NUMBER 314-989-0600
--------------------	------------------	--	-------------------------------------

<input checked="" type="checkbox"/> Main Office Inspection	Next Inspection Date: 04/08
<input type="checkbox"/> Field	
<input type="checkbox"/> Temporary	

PROGRAM SCOPE

The licensee a large medical clinic, performed therapy procedures utilizing licensed materials as described 10 CFR 35.300 and 35.600. In addition, the licensee is approved to perform diagnostic studies under 10 CFR 35.200; however, the licensee had not initiated the "35.200 program." Since the last inspection, the licensee performed two HDR therapies per day or approximately 500 fractions per year using a latest model of Nucletron Microselectron HDR - 105, mainly for breast treatments with occasion of GYN treatments.

At the licensee's clinic, the authorized users also administered I-131 capsules for hyperthyroid and ablation therapies. The licensee ordered unit doses from a licensed pharmacy in St. Louis, MO. The licensee currently employing one physicist/RSO and 13 authorized users at the Ballas clinic located in St. Louis.

Performance Observations

The inspector reviewed written directives for iodine-131, and HDR treatments. No violations were identified during the inspection of the facility. The records indicated that the licensee had conducted multiple fractions of breast therapies with the HDR unit. The HDR unit maintenance record was also reviewed during the inspection, and no safety problem was identified during the quarterly preventive maintenance. The inspector noted that the room contains all the safety systems, and it is located within in a secured dedicated clinic as listed in the license. The licensee secured the HDR unit in an accelerator room by means of locking the main facility entrance at night and a burglar alarm system. In addition, the HDR unit is secured by two padlocks and a heavy gauge of steel cable to the concrete floor. According to the RSO, the facility will be relocated to a new address and facility in August or September 2006, and an amendment is pending to NRC within the next month.